Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.
Company behind weight loss drug Mounjaro, Lilly, has issued an official statement after British woman, Susan McGowan, died ...
A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...
Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...
Mounjaro explained as Adam Lambert speaks out on Instagram live about his drastic weight loss and why he stopped taking ...
Has something changed regarding Eli Lilly or Regeneron's thesis, or is the recent dip an excellent opportunity to invest in ...
An influencer, known as Heather, has organised a party celebrating weight loss jab tirzepatide, close to where NHS worker ...
The new paper, published Wednesday in The New England Journal of Medicine, showed that the compound in the diabetes drug ...